RXi Pharmaceuticals To Present New Data In Its First Phase 2a Clinical Trial With RXI-109

 RXi Pharmaceuticals Corporation

, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that a review of the first two enrolled patients' clinical photographs in the first Phase 2a clinical trial (RXI-109-1301), indicate that treatment with the Company's lead clinical candidate, RXI-109, may be effective in suppressing recurrence of hypertrophic scars at the 3-month time point. Patients will continue to be monitored through 9 months to evaluate if this outcome persists over time. On September 10^th of this year, the Company announced that based on early 1-month observations, the dosing regimen in these trials can be fine-tuned, allowing the Company to more rapidly move forward with treatment optimization for the prevention of scarring after surgery. Today's presentation will provide 3-month photographs from the first two patients enrolled in study RXI-109-1301 that indicate treatment with RXI-109 shows a clinical benefit. The safety information in this ongoing study to date, continues to confirm that RXI-109 is well tolerated with no overt systemic side effects.  Local effects are mild and similar to those seen in the Company's prior Phase 1 clinical trials (erythema, occasional, transient burning or stinging sensation). Complete 3-month results from this trial are expected to be available in Q1 2015. "We are encouraged by the preliminary results in this trial," said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals. "To date, our Phase 2a studies are providing us with exactly the information for which such studies are intended, early information on dosing requirements and observation of a clinical effect of the drug. Having this information in hand now should save money and time going forward in our clinical development as we will incorporate these learnings into future clinical protocols." The presentation will be webcast today, Tuesday, October 7, 2014 at 10:00 a.m. PST, at the 13^th Annual BIO Investor Forum. The webcast will be available on the "Investors" section of the Company's website, www.rxipharma.com.